The future of obesity therapeutics is being written now – be a part of it! Visit the full agenda and speakers here: ...

This includes exploring the use of complement-mediators as combination therapies, discovering innovative indications where ...

Gadoquatrane is being assessed by the US regulator for contrast-enhanced MRI scans of the central nervous system and other ...

Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, ...

While economic evaluations remain the purview of national bodies, the JCA now mirrors the centralised approach of the ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Pharma commercialisation services provider EVERSANA (pharmaphorum's parent company) has acquired Waltz Health, a Chicago ...

Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight with type 2 diabetes, showed that the ...

Current therapies for gMG include AstraZeneca/Alexion's complement C5 inhibitor Ultomiris (ravulizumab), which needs to be ...

The 18th PFS & Injectable Drug Devices Europe Conference returns to London next January, setting the tone for 2026 with a ...

Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday ...